Pharmaceuticals and Clinical Trials

Eli Lilly’s once‑weekly amylin receptor agonist eloralintide yielded 9.5%–20.1% average weight loss over 48 weeks in a 263‑person Phase 2 trial of adults with overweight or obesity without diabetes, according to results published in The Lancet and presented at ObesityWeek 2025 in Atlanta. The drug improved waist circumference, blood pressure, lipids, glycemic markers, and inflammation, was generally well tolerated with mainly GI side effects and fatigue, and Lilly plans Phase 3 studies by year‑end; it is not yet FDA‑approved.